Adderall

Amphetamine/dextroamphetamine
salt mixture (1:1)
an image of the amphetamine skeletal formula
Combination of
Amphetamine aspartate monohydrate25% – stimulant
(12.5% levo; 12.5% dextro)
Amphetamine sulfate25% – stimulant
(12.5% levo; 12.5% dextro)
Dextroamphetamine saccharate25% – stimulant
(0% levo; 25% dextro)
Dextroamphetamine sulfate25% – stimulant
(0% levo; 25% dextro)
Clinical data
Trade namesAdderall, Adderall XR, others
Other namesMixed amphetamine salts; MAS
AHFS/Drugs.comMonograph
MedlinePlusa601234
License data
Dependence
liability		Moderate – high
Routes of
administration		Medical: Oral
Recreational: Oral, insufflation, rectal, sublingual
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityOral: ~90%
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL

Amphetamine mixed salts (also known as amphetamine and dextroamphetamine mixed salts, amphetamine salt combo, or simply amphetamine salts) is a medication used to help attention-deficit hyperactivity disorder (ADHD) and narcolepsy.

It is sold under the brand name Adderall. The drug contains a mixture of the salts of amphetamine and dextroamphetamine. Both of these salts act as stimulants. The drug helps people stay alert and concentrate on what they are doing. It is prescribed to people with ADHD because it helps them stay focused. In those people it can make them calmer. The downside of Adderall is decreased appetite, alongside other side effects.

The sustained-release (or extended-release) formulation is sold under the brand name Adderall XR. This formulation is designed to provide therapeutic effect for longer and keep plasma concentrations of the drugs stable for longer. This is the same as taking two doses 4 hours apart.

Key ingredients of Adderall (amphetamine)

Active ingredients

Inactive ingredients

References

  1. ↑ Vitiello B (April 2008). "Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function". Child and Adolescent Psychiatric Clinics of North America. 17 (2): 459–74, xi. doi:10.1016/j.chc.2007.11.010. PMC 2408826. PMID 18295156.
  2. ↑ Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E (January 2011). "European guidelines on managing adverse effects of medication for ADHD". European Child & Adolescent Psychiatry. 20 (1): 17–37. doi:10.1007/s00787-010-0140-6. eISSN 1435-165X. PMC 3012210. PMID 21042924.
  3. ↑ Kociancic T, Reed MD, Findling RL (March 2004). "Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children". Expert Opinion on Drug Safety. 3 (2): 93–100. doi:10.1517/14740338.3.2.93. eISSN 1744-764X. PMID 15006715. S2CID 31114829.
  4. ↑ Clemow DB, Walker DJ (September 2014). "The potential for misuse and abuse of medications in ADHD: a review". Postgraduate Medicine. 126 (5): 64–81. doi:10.3810/pgm.2014.09.2801. eISSN 1941-9260. PMID 25295651. S2CID 207580823.
  5. ↑ https://en.wikipedia.org/wiki/Special:BookSources/978-1-108-22874-9
  6. ↑ Ingersoll, John (7 July 1971). "Amphetamine, Methamphetamine, and Optical Isomers" (PDF). Federal Register. Bureau of Narcotics and Dangerous Drugs. Retrieved 27 November 2024.{{cite web}}: CS1 maint: deprecated archival service (link)
  7. ↑ https://doi.org/10.1007%2F978-3-030-92392-1_104
  8. ↑ Schwartz A (2013-02-13). "Drowned in a Stream of Prescriptions". New York Times.
  9. ↑ "Medication Guide Adderall XR" (PDF). US Food and Drug Administration (FDA). Retrieved 19 May 2013.